Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2366-1089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States ; day:27 ; month:10 ; year:2016 ; pages:1-9
Oncology and Therapy ; (27.10.2016), 1-9
- Creator
-
Caldeira, Rita
- Contributor
-
Scazafave, Mark
SpringerLink (Online service)
- DOI
-
10.1007/s40487-016-0033-z
- URN
-
urn:nbn:de:1111-2016112317458
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Caldeira, Rita
- Scazafave, Mark
- SpringerLink (Online service)
Other Objects (12)
Rat Models of Hormone Receptor-Positive Breast Cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
The role of ultrasonographic findings for PIK3CA -mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China
Rat Models of Hormone Receptor-Positive Breast Cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
The role of ultrasonographic findings for PIK3CA -mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China
Rat Models of Hormone Receptor-Positive Breast Cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
The role of ultrasonographic findings for PIK3CA -mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization